

### About Deep Pharma Intelligence

**Deep Pharma Intelligence (DPI)** is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

**Deep Pharma Intelligence** is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** – two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

### Our Value Proposition:

#### Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets – technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

#### IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our dashboard to learn more:  
[platform.dkv.global/dashboards/ai-for-drug-discovery](http://platform.dkv.global/dashboards/ai-for-drug-discovery)

#### Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.




### Artificial Intelligence for Drug Discovery Landscape Overview Q1 2022


This 195-page “Artificial Intelligence for Drug Discovery Landscape Overview Q1 2022” aims to provide a comprehensive overview of the industry landscape in what pertains adoption of AI in drug discovery, clinical research and other aspects of pharmaceutical R&D. This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry.

The current release includes insights about **495 AI companies**, **100 corporations**, and **1120+ investors** in the area of pharmaceutical and healthcare artificial intelligence.

#### Some of the key takeaways from this digest include:

- The segment of pharmaceutical AI continues consolidation.
- Pharmaceutical AI sector is “heating up” for investments.
- Big pharma and contract research organizations increasingly compete for AI partnerships.
- In 2021, 10 companies that use AI for DD reached IPO status.
- COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption.
- Despite the crisis, publicly traded companies present rapid growth with reached \$110B of cumulative capitalization as of December 30 2021.





**DEEP  
PHARMA  
INTELLIGENCE**

# Deep Pharma Intelligence

## Artificial Intelligence for Drug Discovery Landscape Overview Q1 2022

Artificial Intelligence for  
Drug Discovery  
Landscape Overview  
Q1 2022

End-to-end Drug  
Development

Early Drug  
Development


Drug  
Repurposing

Preclinical  
Development

Clinical  
Development

Data Processing

AI Companies - 495  
Investors - 1120  
Corporations - 100



## Selected Pharma AI Deals Structure until Q1 2022

AI Companies

Pharma Corporations

AI Companies